Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRI

Marta Tibiletti; James A. Eaden; Josephine H. Naish; Paul J.c. Hughes; John C. Waterton; Matthew J. Heaton; Nazia Chaudhuri; Sarah Skeoch; Ian N. Bruce; Stephen Bianchi; Jim M. Wild; Geoff J.m. Parker

doi:10.1016/j.mri.2022.10.005

Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRI

Marta Tibiletti, James A. Eaden, Josephine H. Naish, Paul J.c. Hughes, John C. Waterton, Matthew J. Heaton, Nazia Chaudhuri, Sarah Skeoch, Ian N. Bruce, Stephen Bianchi, Jim M. Wild, Geoff J.m. Parker

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

115 Downloads (Pure)

Abstract

Purpose: To compare imaging biomarkers from hyperpolarised ¹²⁹Xe ventilation MRI and dynamic oxygen-enhanced MRI (OE-MRI) with standard pulmonary function tests (PFT) in interstitial lung disease (ILD) patients. To evaluate if biomarkers can separate ILD subtypes and detect early signs of disease resolution or progression. Study type: Prospective longitudinal. Population: Forty-one ILD (fourteen idiopathic pulmonary fibrosis (IPF), eleven hypersensitivity pneumonitis (HP), eleven drug-induced ILD (DI-ILD), five connective tissue disease related-ILD (CTD-ILD)) patients and ten healthy volunteers imaged at visit 1. Thirty-four ILD patients completed visit 2 (eleven IPF, eight HP, ten DIILD, five CTD-ILD) after 6 or 26 weeks. Field strength/sequence: MRI was performed at 1.5 T, including inversion recovery T ₁ mapping, dynamic MRI acquisition with varying oxygen levels, and hyperpolarised ¹²⁹Xe ventilation MRI. Subjects underwent standard spirometry and gas transfer testing. Assessment: Five ¹H MRI and two ¹²⁹Xe MRI ventilation metrics were compared with spirometry and gas transfer measurements. Statistical test: To evaluate differences at visit 1 among subgroups: ANOVA or Kruskal-Wallis rank tests with correction for multiple comparisons. To assess the relationships between imaging biomarkers, PFT, age and gender, at visit 1 and for the change between visit 1 and 2: Pearson correlations and multilinear regression models. Results: The global PFT tests could not distinguish ILD subtypes. Percentage ventilated volumes were lower in ILD patients than in HVs when measured with ¹²⁹Xe MRI (HV 97.4 ± 2.6, CTD-ILD: 91.0 ± 4.8 p = 0.017, DI-ILD 90.1 ± 7.4 p = 0.003, HP 92.6 ± 4.0 p = 0.013, IPF 88.1 ± 6.5 p < 0.001), but not with OE-MRI. ¹²⁹Xe reported more heterogeneous ventilation in DI-ILD and IPF than in HV, and OE-MRI reported more heterogeneous ventilation in DI-ILD and IPF than in HP or CTD-ILD. The longitudinal changes reported by the imaging biomarkers did not correlate with the PFT changes between visits. Data conclusion: Neither ¹²⁹Xe ventilation nor OE-MRI biomarkers investigated in this study were able to differentiate between ILD subtypes, suggesting that ventilation-only biomarkers are not indicated for this task. Limited but progressive loss of ventilated volume as measured by ¹²⁹Xe-MRI may be present as the biomarker of focal disease progresses. OE-MRI biomarkers are feasible in ILD patients and do not correlate strongly with PFT. Both OE-MRI and ¹²⁹Xe MRI revealed more spatially heterogeneous ventilation in DI-ILD and IPF.

Original language	English
Pages (from-to)	39-49
Number of pages	11
Journal	Magnetic Resonance Imaging
Volume	95
Early online date	15 Oct 2022
DOIs	https://doi.org/10.1016/j.mri.2022.10.005
Publication status	Published (in print/issue) - 31 Jan 2023

Bibliographical note

Funding Information:
The research leading to these results received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No 116106. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This work was also supported by the National Institute of Health Research (RP-R3-12-027), Medical Research Council (MR/M008894/1) and GlaxoSmithKline (PJCH:BIDS3000032592). The views expressed are those of the authors and not necessarily those of the NHS, NIHR, the Department of Health, GlaxoSmithKline nor the TRISTAN consortium.

Funding Information:
The research leading to these results received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No 116106 . This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This work was also supported by the National Institute of Health Research (RP-R3-12-027), Medical Research Council (MR/M008894/1) and GlaxoSmithKline (PJCH:BIDS3000032592). The views expressed are those of the authors and not necessarily those of the NHS, NIHR, the Department of Health, GlaxoSmithKline nor the TRISTAN consortium.

Publisher Copyright:
© 2022 The Authors

Keywords

Hyperpolarised gas MRI
Oxygen enhanced MRI
Lung MRI
Interstitial lung disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.mri.2022.10.005

1-s2.0-S0730725X22001771-mainFinal published version, 4.68 MBLicence: CC BY

Cite this

Tibiletti, M., Eaden, J. A., Naish, J. H., Hughes, P. J. C., Waterton, J. C., Heaton, M. J., Chaudhuri, N., Skeoch, S., Bruce, I. N., Bianchi, S., Wild, J. M., & Parker, G. J. M. (2023). Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRI. Magnetic Resonance Imaging, 95, 39-49. https://doi.org/10.1016/j.mri.2022.10.005

@article{673b628d0df148daaa4471f5e710c0bb,

title = "Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRI",

abstract = "Purpose: To compare imaging biomarkers from hyperpolarised 129Xe ventilation MRI and dynamic oxygen-enhanced MRI (OE-MRI) with standard pulmonary function tests (PFT) in interstitial lung disease (ILD) patients. To evaluate if biomarkers can separate ILD subtypes and detect early signs of disease resolution or progression. Study type: Prospective longitudinal. Population: Forty-one ILD (fourteen idiopathic pulmonary fibrosis (IPF), eleven hypersensitivity pneumonitis (HP), eleven drug-induced ILD (DI-ILD), five connective tissue disease related-ILD (CTD-ILD)) patients and ten healthy volunteers imaged at visit 1. Thirty-four ILD patients completed visit 2 (eleven IPF, eight HP, ten DIILD, five CTD-ILD) after 6 or 26 weeks. Field strength/sequence: MRI was performed at 1.5 T, including inversion recovery T 1 mapping, dynamic MRI acquisition with varying oxygen levels, and hyperpolarised 129Xe ventilation MRI. Subjects underwent standard spirometry and gas transfer testing. Assessment: Five 1H MRI and two 129Xe MRI ventilation metrics were compared with spirometry and gas transfer measurements. Statistical test: To evaluate differences at visit 1 among subgroups: ANOVA or Kruskal-Wallis rank tests with correction for multiple comparisons. To assess the relationships between imaging biomarkers, PFT, age and gender, at visit 1 and for the change between visit 1 and 2: Pearson correlations and multilinear regression models. Results: The global PFT tests could not distinguish ILD subtypes. Percentage ventilated volumes were lower in ILD patients than in HVs when measured with 129Xe MRI (HV 97.4 ± 2.6, CTD-ILD: 91.0 ± 4.8 p = 0.017, DI-ILD 90.1 ± 7.4 p = 0.003, HP 92.6 ± 4.0 p = 0.013, IPF 88.1 ± 6.5 p < 0.001), but not with OE-MRI. 129Xe reported more heterogeneous ventilation in DI-ILD and IPF than in HV, and OE-MRI reported more heterogeneous ventilation in DI-ILD and IPF than in HP or CTD-ILD. The longitudinal changes reported by the imaging biomarkers did not correlate with the PFT changes between visits. Data conclusion: Neither 129Xe ventilation nor OE-MRI biomarkers investigated in this study were able to differentiate between ILD subtypes, suggesting that ventilation-only biomarkers are not indicated for this task. Limited but progressive loss of ventilated volume as measured by 129Xe-MRI may be present as the biomarker of focal disease progresses. OE-MRI biomarkers are feasible in ILD patients and do not correlate strongly with PFT. Both OE-MRI and 129Xe MRI revealed more spatially heterogeneous ventilation in DI-ILD and IPF.",

keywords = "Hyperpolarised gas MRI, Oxygen enhanced MRI, Lung MRI, Interstitial lung disease",

author = "Marta Tibiletti and Eaden, {James A.} and Naish, {Josephine H.} and Hughes, {Paul J.c.} and Waterton, {John C.} and Heaton, {Matthew J.} and Nazia Chaudhuri and Sarah Skeoch and Bruce, {Ian N.} and Stephen Bianchi and Wild, {Jim M.} and Parker, {Geoff J.m.}",

note = "Funding Information: The research leading to these results received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No 116106. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This work was also supported by the National Institute of Health Research (RP-R3-12-027), Medical Research Council (MR/M008894/1) and GlaxoSmithKline (PJCH:BIDS3000032592). The views expressed are those of the authors and not necessarily those of the NHS, NIHR, the Department of Health, GlaxoSmithKline nor the TRISTAN consortium. Funding Information: The research leading to these results received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No 116106 . This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This work was also supported by the National Institute of Health Research (RP-R3-12-027), Medical Research Council (MR/M008894/1) and GlaxoSmithKline (PJCH:BIDS3000032592). The views expressed are those of the authors and not necessarily those of the NHS, NIHR, the Department of Health, GlaxoSmithKline nor the TRISTAN consortium. Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2023",

month = jan,

day = "31",

doi = "10.1016/j.mri.2022.10.005",

language = "English",

volume = "95",

pages = "39--49",

journal = "Magnetic Resonance Imaging",

issn = "0730-725X",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRI

AU - Tibiletti, Marta

AU - Eaden, James A.

AU - Naish, Josephine H.

AU - Hughes, Paul J.c.

AU - Waterton, John C.

AU - Heaton, Matthew J.

AU - Chaudhuri, Nazia

AU - Skeoch, Sarah

AU - Bruce, Ian N.

AU - Bianchi, Stephen

AU - Wild, Jim M.

AU - Parker, Geoff J.m.

N1 - Funding Information: The research leading to these results received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No 116106. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This work was also supported by the National Institute of Health Research (RP-R3-12-027), Medical Research Council (MR/M008894/1) and GlaxoSmithKline (PJCH:BIDS3000032592). The views expressed are those of the authors and not necessarily those of the NHS, NIHR, the Department of Health, GlaxoSmithKline nor the TRISTAN consortium. Funding Information: The research leading to these results received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No 116106 . This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This work was also supported by the National Institute of Health Research (RP-R3-12-027), Medical Research Council (MR/M008894/1) and GlaxoSmithKline (PJCH:BIDS3000032592). The views expressed are those of the authors and not necessarily those of the NHS, NIHR, the Department of Health, GlaxoSmithKline nor the TRISTAN consortium. Publisher Copyright: © 2022 The Authors

PY - 2023/1/31

Y1 - 2023/1/31

N2 - Purpose: To compare imaging biomarkers from hyperpolarised 129Xe ventilation MRI and dynamic oxygen-enhanced MRI (OE-MRI) with standard pulmonary function tests (PFT) in interstitial lung disease (ILD) patients. To evaluate if biomarkers can separate ILD subtypes and detect early signs of disease resolution or progression. Study type: Prospective longitudinal. Population: Forty-one ILD (fourteen idiopathic pulmonary fibrosis (IPF), eleven hypersensitivity pneumonitis (HP), eleven drug-induced ILD (DI-ILD), five connective tissue disease related-ILD (CTD-ILD)) patients and ten healthy volunteers imaged at visit 1. Thirty-four ILD patients completed visit 2 (eleven IPF, eight HP, ten DIILD, five CTD-ILD) after 6 or 26 weeks. Field strength/sequence: MRI was performed at 1.5 T, including inversion recovery T 1 mapping, dynamic MRI acquisition with varying oxygen levels, and hyperpolarised 129Xe ventilation MRI. Subjects underwent standard spirometry and gas transfer testing. Assessment: Five 1H MRI and two 129Xe MRI ventilation metrics were compared with spirometry and gas transfer measurements. Statistical test: To evaluate differences at visit 1 among subgroups: ANOVA or Kruskal-Wallis rank tests with correction for multiple comparisons. To assess the relationships between imaging biomarkers, PFT, age and gender, at visit 1 and for the change between visit 1 and 2: Pearson correlations and multilinear regression models. Results: The global PFT tests could not distinguish ILD subtypes. Percentage ventilated volumes were lower in ILD patients than in HVs when measured with 129Xe MRI (HV 97.4 ± 2.6, CTD-ILD: 91.0 ± 4.8 p = 0.017, DI-ILD 90.1 ± 7.4 p = 0.003, HP 92.6 ± 4.0 p = 0.013, IPF 88.1 ± 6.5 p < 0.001), but not with OE-MRI. 129Xe reported more heterogeneous ventilation in DI-ILD and IPF than in HV, and OE-MRI reported more heterogeneous ventilation in DI-ILD and IPF than in HP or CTD-ILD. The longitudinal changes reported by the imaging biomarkers did not correlate with the PFT changes between visits. Data conclusion: Neither 129Xe ventilation nor OE-MRI biomarkers investigated in this study were able to differentiate between ILD subtypes, suggesting that ventilation-only biomarkers are not indicated for this task. Limited but progressive loss of ventilated volume as measured by 129Xe-MRI may be present as the biomarker of focal disease progresses. OE-MRI biomarkers are feasible in ILD patients and do not correlate strongly with PFT. Both OE-MRI and 129Xe MRI revealed more spatially heterogeneous ventilation in DI-ILD and IPF.

AB - Purpose: To compare imaging biomarkers from hyperpolarised 129Xe ventilation MRI and dynamic oxygen-enhanced MRI (OE-MRI) with standard pulmonary function tests (PFT) in interstitial lung disease (ILD) patients. To evaluate if biomarkers can separate ILD subtypes and detect early signs of disease resolution or progression. Study type: Prospective longitudinal. Population: Forty-one ILD (fourteen idiopathic pulmonary fibrosis (IPF), eleven hypersensitivity pneumonitis (HP), eleven drug-induced ILD (DI-ILD), five connective tissue disease related-ILD (CTD-ILD)) patients and ten healthy volunteers imaged at visit 1. Thirty-four ILD patients completed visit 2 (eleven IPF, eight HP, ten DIILD, five CTD-ILD) after 6 or 26 weeks. Field strength/sequence: MRI was performed at 1.5 T, including inversion recovery T 1 mapping, dynamic MRI acquisition with varying oxygen levels, and hyperpolarised 129Xe ventilation MRI. Subjects underwent standard spirometry and gas transfer testing. Assessment: Five 1H MRI and two 129Xe MRI ventilation metrics were compared with spirometry and gas transfer measurements. Statistical test: To evaluate differences at visit 1 among subgroups: ANOVA or Kruskal-Wallis rank tests with correction for multiple comparisons. To assess the relationships between imaging biomarkers, PFT, age and gender, at visit 1 and for the change between visit 1 and 2: Pearson correlations and multilinear regression models. Results: The global PFT tests could not distinguish ILD subtypes. Percentage ventilated volumes were lower in ILD patients than in HVs when measured with 129Xe MRI (HV 97.4 ± 2.6, CTD-ILD: 91.0 ± 4.8 p = 0.017, DI-ILD 90.1 ± 7.4 p = 0.003, HP 92.6 ± 4.0 p = 0.013, IPF 88.1 ± 6.5 p < 0.001), but not with OE-MRI. 129Xe reported more heterogeneous ventilation in DI-ILD and IPF than in HV, and OE-MRI reported more heterogeneous ventilation in DI-ILD and IPF than in HP or CTD-ILD. The longitudinal changes reported by the imaging biomarkers did not correlate with the PFT changes between visits. Data conclusion: Neither 129Xe ventilation nor OE-MRI biomarkers investigated in this study were able to differentiate between ILD subtypes, suggesting that ventilation-only biomarkers are not indicated for this task. Limited but progressive loss of ventilated volume as measured by 129Xe-MRI may be present as the biomarker of focal disease progresses. OE-MRI biomarkers are feasible in ILD patients and do not correlate strongly with PFT. Both OE-MRI and 129Xe MRI revealed more spatially heterogeneous ventilation in DI-ILD and IPF.

KW - Hyperpolarised gas MRI

KW - Oxygen enhanced MRI

KW - Lung MRI

KW - Interstitial lung disease

UR - https://pure.ulster.ac.uk/en/publications/673b628d-0df1-48da-aa44-71f5e710c0bb

UR - https://linkinghub.elsevier.com/retrieve/pii/S0730725X22001771

UR - http://www.scopus.com/inward/record.url?scp=85140320119&partnerID=8YFLogxK

U2 - 10.1016/j.mri.2022.10.005

DO - 10.1016/j.mri.2022.10.005

M3 - Article

C2 - 36252693

SN - 0730-725X

VL - 95

SP - 39

EP - 49

JO - Magnetic Resonance Imaging

JF - Magnetic Resonance Imaging

ER -

Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRI

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this